[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609982":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":10,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients provide blood samples collected during regularly scheduled appointments and have medical records reviewed throughout the study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Non-Interventional Study","Non-interventional study",[9],[20,21],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[23],{"name":24,"affiliation":25,"role":26},"Madeleine B. O'Keefe, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[34],{"facility":25,"status":10,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Rochester","Minnesota","55905","United States",{"type":40,"coordinates":41},"Point",[42,43],-92.4699,44.02163,{"lat":43,"lon":42},[46,47,50],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":48,"role":30,"phone":49,"phoneExt":10,"email":10},"Pediatric Research","507-266-2942",{"name":24,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100609982",false,"NCT07221656","Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration","Inclusion Criteria:\n\n* Acute lymphoblastic leukemia\u002Flymphoma being treated by the pediatric hematology team\n* Receiving calaspargase as part of treatment for malignancy\n\nExclusion Criteria:\n\n* Age \\> 21 years\n* Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm\n* Pregnancy","ALL","21 Years",{"count":61,"type":62},20,"ESTIMATED","OBSERVATIONAL","This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.",[66,67],"Childhood Acute Lymphoblastic Leukemia","Childhood Lymphoblastic Lymphoma","NOT_YET_RECRUITING","2026-03-31",{"date":71,"type":72},"2026-04-02","ACTUAL",{"date":74,"type":62},"2027-02-01",{"date":76,"type":62},"2028-12-31",{"name":5,"class":6},1]